NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease

Nicotinamide adenine dinucleotide (NAD) replenishment therapy using nicotinamide riboside (NR) shows promise for Parkinson’s disease (PD) and other neurodegenerative disorders. However, the optimal dose of NR remains unknown, and doses exceeding 2000 mg daily have not been tested in humans. To evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Berven, Haakon, Kverneng, Simon, Sheard, Erika, Søgnen, Mona, Af Geijerstam, Solveig Amdahl, Haugarvoll, Kristoffer, Skeie, Geir-Olve, Dölle, Christian, Tzoulis, Charalampos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684646/
https://www.ncbi.nlm.nih.gov/pubmed/38016950
http://dx.doi.org/10.1038/s41467-023-43514-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684646/
https://www.ncbi.nlm.nih.gov/pubmed/38016950
http://dx.doi.org/10.1038/s41467-023-43514-6

Ejemplares similares